High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$4.2M
$4,219,553
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
SYRE
M
Spyre Therapeutics, Inc.
Sloan Sheldon
• Officer • Chief Medical Officer
Other
2026-04-01
$172,370
|
||||||
| SYRE |
Spyre Therapeutics, Inc.
|
Officer • Chief Medical Officer
Other
|
2026-04-01 | $172,370 | M | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-04-01 | $64,974 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-04-01 | $305,102 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
Other
|
2026-04-01 | $108,750 | M | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-04-01 | $132,588 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-04-01 | $607,325 | S | Form 4 |
|
SYRE
S
Spyre Therapeutics, Inc.
Sloan Sheldon
• Officer • Chief Medical Officer
10b5-1 Sell
2026-04-01
$397,900
|
||||||
| SYRE |
Spyre Therapeutics, Inc.
|
Officer • Chief Medical Officer
10b5-1 Sell
|
2026-04-01 | $397,900 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-03-03 | $93,288 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
Other
|
2026-03-03 | $36,250 | M | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CFO
10b5-1 Sell
|
2026-03-03 | $8,332 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-03-02 | $386,659 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-03-02 | $246,207 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-02-02 | $30,452 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2026-02-02 | $461,593 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-12-01 | $315,886 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-12-01 | $119,469 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-11-03 | $651,225 | S | Form 4 |
| SYRE |
Spyre Therapeutics, Inc.
|
CEO
10b5-1 Sell
|
2025-11-03 | $398,553 | S | Form 4 |